Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
April 19th 2024According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.
ASCRS 2024: International data are forthcoming in corneal endothelial disease treatment
April 16th 2024At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.